Your search history is turned on.
Date: May 7, 2021 Jurisdictions: Alberta, British Columbia, Ontario
Microsoft Word - VANCOUVER-#51257425-v3-iCo_-_Material_Change_Report.docx FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company iCo Therapeutics Inc. 6th Floor, 777 Hornby Street Vancouver, BC V6Z 2T3 Item 2 Date of Material Change April 27, 2021 Item 3 News Release The news release announcing the material change was issued o...
Date: May 5, 2021 Jurisdictions: Alberta
Microsoft Word - VANCOUVER-#51256960-v3-iCo_Report_of_Exempt_Distribution_(April_2021) (002).DOCX 1 51256960.3 Form 45-106F1 Report of Exempt Distribution A. General Instructions 1. Filing instructions An issuer or underwriter that is required to file a report of exempt distribution and pay the applicable fee must file the report and pay the fee as f...
Date: April 29, 2021 Jurisdictions: Alberta, British Columbia, Ontario
FORM 52-109FV1 FORM 52-109FV1 CERTIFICATION OF ANNUAL FILINGS VENTURE ISSUER BASIC CERTIFICATE I, William Jarosz, Chief Executive Officer of iCo Therapeutics Inc. certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incor...
FORM 52-109FV1 FORM 52-109FV1 CERTIFICATION OF ANNUAL FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Michael Liggett, Chief Financial Officer of iCo Therapeutics Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are inc...
1 51100985.4 MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE YEAR ENDED DCEMBER 31, 2020 This managements discussion and analysis (MD&A) has been prepared as of April 29, 2021 and should be read in conjunction with the consolidated financial statements of iCo Therapeutics Inc. (iCo or the Company) fo...
FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, _______________________, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission...
Microsoft Word - ASC_LIB1-#5334409-v1-13-501_F1_Consolidation_Eff_Mar_1_2017.DOCX Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 RE...
Microsoft Word - iCo Therapeutics Inc (Dec 2020).docx iCo Therapeutics Inc. Consolidated Financial Statements December 31, 2020 and 2019 (in Canadian dollars) PricewaterhouseCoopers LLP PricewaterhouseCoopers Place, 250 Howe Street, Suite 1400, Vancouver, British Columbia, Canada V6C 3S7 T: +1 604 806 7000, F: +1 604 806 7806 PwC refers to Price...
iCo Therapeutics Announces 2020 Year End Financial Results and Resignation of Susan Koppy Vancouver, British Columbia--(Newsfile Corp. - April 29, 2021) - iCo Therapeutics ("iCo" or the "Company") (TSXV: ICO) (OTC: ICOTF) today reported financial results for the year ended December 31, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Fi...
Date: April 27, 2021 Jurisdictions: Alberta, British Columbia, Ontario
iCo Therapeutics Inc. Announces Closing of Upsized Subscription Receipt Private Placement Vancouver, British Columbia--(Newsfile Corp. - April 27, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTC: ICOTF) ("iCo" or the "Company") is pleased to announce that it has closed its previously announced private placement (the "Financing") in connection with its proposed business combination with Satellos Bio...